Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial’s Use of Healthcare Systems Data for Clinical Follow-Up
Clinical Oncology · 2026-08 · 56 · 104162
DOI: 10.1016/j.clon.2026.104162 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Oncology, 2026-08. Verfasst von K Shu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Tongling University, China. Die Arbeit nennt 4 Literaturangaben. Gefördert von: Anhui Provincial Department of Education.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Tongling University, China.
- Anhui Vocational and Technical University, China. Electronic address: chengmengting@gou.edu.pl.
Förderung
- Anhui Provincial Department of Education
Zitieren
APA
Shu, K., & Cheng, M. (2026). Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial’s Use of Healthcare Systems Data for Clinical Follow-Up. Clinical Oncology, 56, 104162. https://doi.org/10.1016/j.clon.2026.104162
Vancouver
Shu K, Cheng M. Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial’s Use of Healthcare Systems Data for Clinical Follow-Up. Clinical Oncology. 2026;56:104162. doi:10.1016/j.clon.2026.104162
BibTeX
@article{Shu2026,
author = {Shu, K and Cheng, M},
title = {Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial’s Use of Healthcare Systems Data for Clinical Follow-Up},
journal = {Clinical Oncology},
year = {2026},
volume = {56},
pages = {104162},
doi = {10.1016/j.clon.2026.104162}
}
EUVIMED